Arcus Biosciences (NYSE:RCUS) 2026 Conference Transcript

Summary of Arcus Therapeutics Conference Call Company and Industry Overview - Company: Arcus Therapeutics - Industry: Oncology, specifically focusing on HIF-2 inhibitors for cancer treatment Key Points and Arguments Casdatifan vs. Belzutifan - Differentiation: Casdatifan is positioned as a best-in-class HIF-2 inhibitor compared to Merck's belzutifan, primarily due to its pharmacokinetic and pharmacodynamic (PK/PD) profile, which allows for more effective targeting of the cancer [2][6] - Clinical Efficacy: In late-line settings, casdatifan shows a primary progression rate of approximately 18% compared to belzutifan's nearly 35% [3] - Response Rates: The confirmed response rate for casdatifan is about 35% across 120 patients, with the 100 mg cohort showing a 45% response rate, significantly higher than belzutifan's over 20% [4] - Progression-Free Survival (PFS): Median PFS for casdatifan is reported at 12.2 months, with the 100 mg cohort exceeding 15 months, while belzutifan shows around 5.6 months [4] Biomarker Data - Erythropoietin Suppression: Casdatifan demonstrates deeper and more durable suppression of erythropoietin production compared to belzutifan, which loses its pharmacodynamic effect after about 9 weeks [5] - Correlation with Efficacy: There is a clear correlation between the ability to suppress erythropoietin and clinical outcomes, reinforcing the efficacy of casdatifan [5] Treatment Durability - Prolonged Disease Control: Patients on casdatifan can experience prolonged disease control, with some remaining stable for over two years, indicating a non-toxic mechanism that allows the immune system to strengthen [10][11] - Resistance Mechanism: There is no known mechanism for resistance to HIF-2 inhibitors, which is a significant advantage over other cancer therapies [12] Clinical Development and Future Studies - ARC-20 Study: The study has added multiple cohorts to evaluate different dosing regimens and combinations, with a steady stream of data expected over the next two to three years [25] - Upcoming Data: Key datasets expected include the combination of casdatifan with cabozantinib and anti-PD-1 therapies, with initial results anticipated between July and October [26][30] Market Position and Strategy - TKI Partner Selection: Cabozantinib was chosen as the TKI partner due to its familiarity and better tolerability among clinicians compared to lenvatinib, which has more complex dosing [32][34] - Regulatory Strategy: The primary endpoint for the PEAK-1 study is PFS, which aligns with regulatory standards for second-line RCC treatments, and is expected to maximize the probability of success [43][44] Competitive Landscape - Market Dynamics: The use of HIF-2 inhibitors is expected to expand across multiple lines of therapy, potentially leading to a larger market opportunity compared to other tumor types where treatment options are limited [69] Additional Important Insights - Anemia Management: Anemia rates for casdatifan are comparable to belzutifan, with ongoing improvements in managing these side effects expected as clinical experience grows [21][23] - Subsequent Therapy Considerations: The geographic footprint for belzutifan usage is limited outside the U.S., which may not significantly impact the subsequent therapy landscape for casdatifan [53] This summary encapsulates the critical insights from the conference call regarding Arcus Therapeutics' strategic positioning, clinical data, and future outlook in the oncology market.